metricas
covid
Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Refractory juvenile dermatomyositis: Response to tofacitinib
Journal Information

Statistics

Follow this link to access the full text of the article

Letter to the Editor
Refractory juvenile dermatomyositis: Response to tofacitinib
Dermatomiositis juvenil refractaria: respuesta al tofacitinib
Qingfang Zhoua, Ruohang Wengb, Yu Xiab,
Corresponding author
xiayu790921@sina.com

Corresponding author.
a Shenzhen Children's Hospital, China Medical University, Shenzhen, China
b Department of Immunology, Shenzhen Children's Hospital, Shenzhen, China
Read
Not available
Times
was read the article
Total PDF
Total HTML
Share statistics
 array:23 [
  "pii" => "S2387020621006951"
  "issn" => "23870206"
  "doi" => "10.1016/j.medcle.2021.03.031"
  "estado" => "S300"
  "fechaPublicacion" => "2022-01-21"
  "aid" => "5671"
  "copyrightAnyo" => "2021"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "cor"
  "cita" => "Med Clin. 2022;158:95-6"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "en" => array:18 [
      "pii" => "S0025775321002359"
      "issn" => "00257753"
      "doi" => "10.1016/j.medcli.2021.03.022"
      "estado" => "S300"
      "fechaPublicacion" => "2022-01-21"
      "aid" => "5671"
      "documento" => "simple-article"
      "crossmark" => 1
      "subdocumento" => "cor"
      "cita" => "Med Clin. 2022;158:95-6"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:11 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
        "titulo" => "Refractory juvenile dermatomyositis&#58; Response to tofacitinib"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "95"
            "paginaFinal" => "96"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Dermatomiositis juvenil refractaria&#58; respuesta al tofacitinib"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Fig&#46; 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 1558
                "Ancho" => 2500
                "Tamanyo" => 203816
              ]
            ]
            "descripcion" => array:1 [
              "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; X-ray findings of calcification on the patient&#39;s two legs before being treated with tofacitinib&#44; there were a lot of calcifications on both legs&#46; &#40;B&#41; X-ray findings of calcification on the patient&#39;s two legs&#44; after 17 months&#8217; treatment with tofacitinib&#44; calcifications regressed&#46; In &#40;A&#41;&#44; the white dot image in the figure is calcification as shown by the red arrow&#46; In &#40;B&#41;&#44; the calcification as shown by the red arrow has disappeared&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Qingfang Zhou, Ruohang Weng, Yu Xia"
            "autores" => array:3 [
              0 => array:2 [
                "nombre" => "Qingfang"
                "apellidos" => "Zhou"
              ]
              1 => array:2 [
                "nombre" => "Ruohang"
                "apellidos" => "Weng"
              ]
              2 => array:2 [
                "nombre" => "Yu"
                "apellidos" => "Xia"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2387020621006951"
          "doi" => "10.1016/j.medcle.2021.03.031"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020621006951?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775321002359?idApp=UINPBA00004N"
      "url" => "/00257753/0000015800000002/v1_202201120526/S0025775321002359/v1_202201120526/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2387020621006896"
    "issn" => "23870206"
    "doi" => "10.1016/j.medcle.2021.03.028"
    "estado" => "S300"
    "fechaPublicacion" => "2022-01-21"
    "aid" => "5670"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46;"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "cor"
    "cita" => "Med Clin. 2022;158:96-7"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
      "titulo" => "Erenumab for the treatment of chronic resistant migraine"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "96"
          "paginaFinal" => "97"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Erenumab para el tratamiento de migra&#241;a cr&#243;nica farmacorresistente"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Almudena Layos-Romero, Alberto Andr&#233;s L&#243;pez, Laura Rojas Bartolom&#233;"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "Almudena"
              "apellidos" => "Layos-Romero"
            ]
            1 => array:2 [
              "nombre" => "Alberto Andr&#233;s"
              "apellidos" => "L&#243;pez"
            ]
            2 => array:2 [
              "nombre" => "Laura"
              "apellidos" => "Rojas Bartolom&#233;"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0025775321002347"
        "doi" => "10.1016/j.medcli.2021.03.021"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775321002347?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020621006896?idApp=UINPBA00004N"
    "url" => "/23870206/0000015800000002/v1_202201220701/S2387020621006896/v1_202201220701/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S2387020621006938"
    "issn" => "23870206"
    "doi" => "10.1016/j.medcle.2021.03.030"
    "estado" => "S300"
    "fechaPublicacion" => "2022-01-21"
    "aid" => "5679"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46;"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "cor"
    "cita" => "Med Clin. 2022;158:94-5"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
      "titulo" => "Bradycardia due to remdesivir&#58; Report of two cases"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "94"
          "paginaFinal" => "95"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Bradicardia por remdesivir&#58; estudio de dos casos"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Laura Cebri&#225;n Lara, Eva Hern&#224;ndez Lorente, Paula Garc&#237;a Llopis"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "Laura"
              "apellidos" => "Cebri&#225;n Lara"
            ]
            1 => array:2 [
              "nombre" => "Eva"
              "apellidos" => "Hern&#224;ndez Lorente"
            ]
            2 => array:2 [
              "nombre" => "Paula"
              "apellidos" => "Garc&#237;a Llopis"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0025775321002438"
        "doi" => "10.1016/j.medcli.2021.03.030"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775321002438?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020621006938?idApp=UINPBA00004N"
    "url" => "/23870206/0000015800000002/v1_202201220701/S2387020621006938/v1_202201220701/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
    "titulo" => "Refractory juvenile dermatomyositis&#58; Response to tofacitinib"
    "tieneTextoCompleto" => true
    "saludo" => "Dear Editor&#58;"
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "95"
        "paginaFinal" => "96"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Qingfang Zhou, Ruohang Weng, Yu Xia"
        "autores" => array:3 [
          0 => array:3 [
            "nombre" => "Qingfang"
            "apellidos" => "Zhou"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Ruohang"
            "apellidos" => "Weng"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:4 [
            "nombre" => "Yu"
            "apellidos" => "Xia"
            "email" => array:1 [
              0 => "xiayu790921@sina.com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Shenzhen Children&#39;s Hospital&#44; China Medical University&#44; Shenzhen&#44; China"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Department of Immunology&#44; Shenzhen Children&#39;s Hospital&#44; Shenzhen&#44; China"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Dermatomiositis juvenil refractaria&#58; respuesta al tofacitinib"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig&#46; 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1558
            "Ancho" => 2500
            "Tamanyo" => 203816
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; X-ray findings of calcification on the patient&#39;s two legs before being treated with tofacitinib&#44; there were a lot of calcifications on both legs&#46; &#40;B&#41; X-ray findings of calcification on the patient&#39;s two legs&#44; after 17 months&#8217; treatment with tofacitinib&#44; calcifications regressed&#46; In &#40;A&#41;&#44; the white dot image in the figure is calcification as shown by the red arrow&#46; In &#40;B&#41;&#44; the calcification as shown by the red arrow has disappeared&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Juvenile dermatomyositis &#40;JDM&#41; is a chronic systemic autoimmune disease&#44; mainly manifested as muscle weakness and rash&#44; which can also be accompanied by calcifications and even involves lung&#44; heart and other organs&#46; Hence&#44; it is necessary to adopt timely and effective therapy to stop the progression of the disease damage&#46; Glucocorticoids and disease modifying anti-rheumatic drugs &#40;DMARDs&#41; are a main therapy&#46; However&#44; patients with JDM who are unresponsive to corticosteroids or other immunosuppressive medications face poor outcome and suffer from various sequelae of the disease&#46;<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1&#44;2</span></a> Therefore&#44; it is important to find new treatments for refractory JDM&#46; Recently&#44; multiple centers have tried biologics including rituximab&#44; abatacept&#44; tofacitinib and tocilizumab for refractory dermatomyositis&#46; Though some trials fail to reach its primary end point&#44; janus-Kinase &#40;JAK&#41; inhibitor tofacitinib for refractory dermatomyositis patients showed an overall good efficacy&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">In JDM&#44; type I interferon participates in the pathophysiological process by inducing the expression of proinflammatory cytokines&#46; In addition&#44; STAT3 can be transferred to mitochondria and might involve in regulating the release of mitochondrial calcium pool&#46; This is of potential significance to calcification in patients with dermatomyositis&#46; Herein&#44; JAK inhibitors may be a meaningful treatment for JDM with calcification&#46;<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">3&#44;4</span></a> We did like to report a successful case of treating extensive calcifications in refractory JDM with tofacitinib&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Our patient was a 2&#46;1-year-old child whose clinical manifestation is severe proximal muscle weakness&#44; with the score on the childhood myositis assessment scale &#40;CMAS&#41; score of 26&#47;52 and Gottron&#39;s papules over his hands&#8217; small and large joints&#46; His both legs were covered with lumps&#46; The results of laboratory tests showed the following abnormal values&#58; high lactate dehydrogenase &#40;LDH<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>387<span class="elsevierStyleHsp" style=""></span>U&#47;L&#44; reference range 155&#8211;345<span class="elsevierStyleHsp" style=""></span>U&#47;L&#41; and erythrocyte sedimentation rate &#40;ESR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>43<span class="elsevierStyleHsp" style=""></span>mm&#47;h&#44; reference range 0&#8211;15<span class="elsevierStyleHsp" style=""></span>mm&#47;h&#41;&#46; Antinuclear antibodies were positive with a titer of 1&#58;100&#46; The myositis-specific autoantibodies screening demonstrated positive anti-NXP2 and X-ray of thighs demonstrated extensive deep calcium deposits&#46; Biopsy for the subcutaneous mass on the left leg showed calcified nodules&#44; and biopsy for the muscle showed inflammatory musculopathy&#44; which are consistent with muscle damage changes&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">According to the Bohan and Peter criteria&#44; the patient was diagnosed with cutaneous calcinosis with JDM&#46; He started to be treated with oral prednisolone 2<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;day&#44; intravenous immunoglobulin 2<span class="elsevierStyleHsp" style=""></span>g&#47;kg&#41;&#44; subcutaneous methotrexate&#44; oral cyclosporine &#40;5<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;day&#41;&#46; As a result&#44; the laboratory tests significantly improved thanks to the treatment&#46; CMAS score was from 26&#47;52 to 36&#47;52 and the skin lesions slightly improved&#44; but this cannot prevent the progression of calcifications &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>A&#41;&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">So he began to be treated with tofacitinib at 4 because of muscle weakness without complete remission and progression in calcifications&#46; He accepted dose escalation until the optimal tolerated treatment doses applicable to his weight and renal function &#40;5<span class="elsevierStyleHsp" style=""></span>mg&#47;day&#41;&#46; Six months later&#44; the skin lesions saw complete remission and CMAS score was from 36&#47;52 to 40&#47;52&#44; and physician global VAS score from 8 to 4&#46; Inflammation of calcifications were fully resolved&#46; 17 months later&#44; CMAS score was from 40&#47;52 to 48&#47;52&#44; physician global VAS score from 4 to 2 and calcifications became either stable or regressive&#46; There were no new lumps underneath the skin &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>B&#41;&#46; During the treatment with tofacitinib&#44; there was no hospitalization due to infectious diseases&#46; The number of white blood cells had never decreased seriously &#40;3&#46;87&#8211;10&#46;00<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>&#47;L&#41;&#44; so had the number of neutrophils &#40;2&#46;39&#8211;4&#46;34<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>&#47;L&#41;&#46; Blood lipids&#44; liver enzymes and creatinine were within the normal ranges&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">This is consistent with the report of Yuchuan Ding and his colleagues &#40;2020&#41;&#44; which highlighted tofacitinib in significantly improving the rash and muscle strength of 25 refractory JDM patients&#46;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a> We observed that tofacitinib also can prevent rapidly progressive calcification&#44; and some calcifications began to shrink when being treated with tofacitinib&#46; Tofacitinib may be an effective and safe therapy for extensive calcifications in refractory JDM patients&#46; But our case has been a difficulty for many years&#44; so the possibility of its symptoms to be completely reversible still remains uncertain&#46; However&#44; for the first time in two years&#44; we are able to significantly change the process of calcification&#44; which proved that the symptoms have improved&#46; Further prospective studies are required to explore the potential safety and efficacy of JDM in JAK inhibitor&#46;</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Ethics approval and consent to participate</span><p id="par0035" class="elsevierStylePara elsevierViewall">In the study&#44; the use of human data was clearly approved by the Ethics Committee of Shenzhen Children&#39;s Hospital&#44; and obtained the informed consents of the patient&#8217; parents&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Fundings</span><p id="par0040" class="elsevierStylePara elsevierViewall">This study was supported by <span class="elsevierStyleGrantSponsor" id="gs1">Sanming Project of Medicine in Shenzhen</span> &#40;<span class="elsevierStyleGrantNumber" refid="gs1">SZSM201812002</span>&#41; and <span class="elsevierStyleGrantSponsor" id="gs2">Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties</span> &#40;No&#46; <span class="elsevierStyleGrantNumber" refid="gs2">SZGSP012</span>&#41;&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Conflict of interest</span><p id="par0045" class="elsevierStylePara elsevierViewall">All the authors declare that they have no conflict of interest&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:4 [
        0 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Ethics approval and consent to participate"
        ]
        1 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Fundings"
        ]
        2 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Conflict of interest"
        ]
        3 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "multimedia" => array:1 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig&#46; 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1558
            "Ancho" => 2500
            "Tamanyo" => 203816
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; X-ray findings of calcification on the patient&#39;s two legs before being treated with tofacitinib&#44; there were a lot of calcifications on both legs&#46; &#40;B&#41; X-ray findings of calcification on the patient&#39;s two legs&#44; after 17 months&#8217; treatment with tofacitinib&#44; calcifications regressed&#46; In &#40;A&#41;&#44; the white dot image in the figure is calcification as shown by the red arrow&#46; In &#40;B&#41;&#44; the calcification as shown by the red arrow has disappeared&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:5 [
            0 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical practice guidance for juvenile dermatomyositis &#40;JDM&#41; 2018-update"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "I&#46; Kobayashi"
                            1 => "S&#46; Akioka"
                            2 => "N&#46; Kobayashi"
                            3 => "N&#46; Iwata"
                            4 => "S&#46; Takezaki"
                            5 => "H&#46; Nakaseko"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/14397595.2020.1718866"
                      "Revista" => array:6 [
                        "tituloSerie" => "Mod Rheumatol"
                        "fecha" => "2020"
                        "volumen" => "30"
                        "paginaInicial" => "411"
                        "paginaFinal" => "423"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31955618"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis&#58; a pilot study and literature review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "Z&#46; Yu"
                            1 => "L&#46; Wang"
                            2 => "M&#46; Quan"
                            3 => "T&#46; Zhang"
                            4 => "H&#46; Song"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/rheumatology/keaa558"
                      "Revista" => array:3 [
                        "tituloSerie" => "Rheumatology &#40;Oxford&#44; England&#41;"
                        "fecha" => "2020"
                        "itemHostRev" => array:3 [
                          "pii" => "S0923753419346952"
                          "estado" => "S300"
                          "issn" => "09237534"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "JAK inhibitor improves type I interferon induced damage&#58; proof of concept in dermatomyositis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Ladislau"
                            1 => "X&#46; Su&#225;rez-Calvet"
                            2 => "S&#46; Toquet"
                            3 => "O&#46; Landon-Cardinal"
                            4 => "D&#46; Amelin"
                            5 => "M&#46; Depp"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/brain/awy105"
                      "Revista" => array:5 [
                        "tituloSerie" => "Brain&#58; J Neurol"
                        "fecha" => "2018"
                        "volumen" => "141"
                        "paginaInicial" => "1609"
                        "paginaFinal" => "1621"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Janus kinase &#40;JAK&#41; inhibition with baricitinib in refractory juvenile dermatomyositis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46; Kim"
                            1 => "S&#46; Dill"
                            2 => "M&#46; O&#8217;Brien"
                            3 => "L&#46; Vian"
                            4 => "X&#46; Li"
                            5 => "M&#46; Manukyan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2020-218690"
                      "Revista" => array:2 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2020"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "Y&#46; Ding"
                            1 => "B&#46; Huang"
                            2 => "Y&#46; Wang"
                            3 => "J&#46; Hou"
                            4 => "Y&#46; Chi"
                            5 => "Z&#46; Zhou"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2020-218582"
                      "Revista" => array:2 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2020"
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/23870206/0000015800000002/v1_202201220701/S2387020621006951/v1_202201220701/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "43309"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Letters to the Editor"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/23870206/0000015800000002/v1_202201220701/S2387020621006951/v1_202201220701/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020621006951?idApp=UINPBA00004N"
]
Article information
ISSN: 23870206
Original language: English
The statistics are updated each day

Follow this link to access the full text of the article

es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos